cro.directory
← Compare landing

InfinixBio vs WuXi AppTec

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryInfinixBioWuXi AppTec
SummaryColumbus, Ohio-based contract research organization offering assay development, GLP-compliant preclinical studies including PK and immunogenicity testing, and Phase 1 and 2 clinical testing support for biotech and pharma sponsors.Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Services
  • Discovery Research
  • Target Identification & Validation
  • Preclinical In Vivo Studies
  • In Vivo PK / PD Studies
  • Specialized & Large-Animal Models
  • Bioanalysis
  • Immunogenicity Assays (ADA / NAb)
  • Biomarker Assays
  • Clinical Trial Services
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Discovery Research
  • Target Identification & Validation
  • High-Throughput Screening
  • Medicinal Chemistry
  • Computational & In-Silico Drug Discovery
  • Protein Engineering
  • Preclinical In Vitro Studies
  • In Vitro Pharmacology
  • In Vitro ADME / DMPK
  • Safety Pharmacology
  • Genetic Toxicology
  • Preclinical In Vivo Studies
  • In Vivo Efficacy Models
  • In Vivo PK / PD Studies
  • GLP Toxicology
  • Carcinogenicity Studies
  • DART (Reproductive & Developmental Toxicology)
  • Specialized & Large-Animal Models
  • Bioanalysis
  • LC-MS Bioanalysis (Small Molecule)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • Immunogenicity Assays (ADA / NAb)
  • Biomarker Assays
  • Flow Cytometry Services
  • Clinical Trial Services
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Data Management & eClinical
  • Biostatistics & Statistical Programming
  • Pharmacovigilance & Drug Safety
  • Medical Writing
  • Regulatory Affairs
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • Translational Research
Modalities
  • Gene Therapy
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Antibody-Drug Conjugate (ADC)
  • Oligonucleotide
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Peptide
  • Vaccine
IndicationsData not yet provided.
  • Oncology
  • Immunology
  • Neurology
  • Psychiatry
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Rare Disease
  • Respiratory
  • Dermatology
  • Ophthalmology
  • Gastroenterology
  • Nephrology
  • Women's Health
Phases
  • Discovery
  • Preclinical (IND-Enabling)
  • Phase I
  • Phase II
  • Discovery
  • Preclinical (General)
  • Preclinical (IND-Enabling)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
Sourcing models
  • Full-Service Outsourcing (FSO)
  • Full-Service Outsourcing (FSO)
Locations
  • Columbus, OH, Columbus, OH, US
  • Headquarters, Shanghai, Pudong, China
  • Global Operations, Asia, Europe, North America
CertificationsData not yet provided.Data not yet provided.

Find similar companies

InfinixBio alternatives · WuXi AppTec alternatives

Markdown mirror: /compare/infinixbio/wuxiapptec.md